Aktie A2QA48 ACTINIUM PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Actinium Pharmaceuticals, Inc.

Aktien

A2QA48

US00507W2061

ATNM

Markt geschlossen - Nyse
Andere Börsenplätze
 22:00:00 26.04.2024 		% 5 Tage % 1. Jan.
6,87 USD +4,73 % Intraday Chart für Actinium Pharmaceuticals, Inc. +0,29 % +35,24 %
26.04. Actinium Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
18.04. Actinium Pharmaceuticals, Inc. hebt die Fähigkeit von Iomab-B hervor, die Hochrisiko-TP53-Mutation zu überwinden, was zu einer signifikanten Verbesserung des Gesamtüberlebens bei Patienten mit aktiver rezidivierter refraktärer AML auf der Europäischen Jahrestagung für Knochenmarktransplantation führt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"
InvestorBrandMedia: Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
InvestorBrandMedia: Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting and Exposition
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QA48 Aktie
  4. Nachrichten Actinium Pharmaceuticals, Inc.
  5. Andere Sprachen